hypertrophic cardiomyopathy

News

ESC26: Cytokinetics' big data reveal for Myqorzo impresses

Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of Myqorzo in non-obstructive hypertrophic cardiomyopathy at ESC 2026.

News

Cytokinetics' cardiomyopathy drug cleared for NHS use

Cytokinetics gets simultaneous MHRA and NICE approvals for hypertrophic cardiomyopathy (HCM) therapy Myqorzo.

News

Two more biotechs, Attovia and Braveheart, join the IPO line

The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia and Braveheart the latest to make their intentions known.

News

After rival fails, Cytokinetics could broaden Myqorzo label

Cytokinetics' Myqorzo has succeeded where BMS's first-to-market Camzyos failed, with a positive trial in non-obstructive hypertrophic cardiomyopathy.

News

Failed trial knocks back wider use of BMS' Camzyos

Bristol-Myers Squibb's Camzyos has fallen short in a trial in non-obstructive hypertrophic cardiomyopathy, denting its growth prospects.

News

Cytokinetics' president and chief executive Robert Blum

FDA kicks off review of Cytokinetics' aficamten for HCM

Cytokinetics should hear back from the FDA next September about its application for Camzyos rival aficamten in obstructive hypertrophic cardiomyopathy

ESC26: Cytokinetics' big data reveal for Myqorzo impresses

Cytokinetics' cardiomyopathy drug cleared for NHS use

Two more biotechs, Attovia and Braveheart, join the IPO line

After rival fails, Cytokinetics could broaden Myqorzo label

Failed trial knocks back wider use of BMS' Camzyos

FDA kicks off review of Cytokinetics' aficamten for HCM

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

hypertrophic cardiomyopathy

Editor's Picks